Docoh
Loading...

123 results

Filter options loading...
Top filers
Top filing types
Recent filing years
DEF 14A
PCSA Processa Pharmaceuticals Inc
20 Sep 21
Definitive proxy
2:51pm
with respect to the issuance thereof for any purpose. The Board of Directors does not intend to issue any common stock except on terms which the Board … of Directors determines it to be necessary or appropriate for the purpose of soliciting additional proxies to approve Proposal 1. We currently do not intend
PRE 14A
PCSA Processa Pharmaceuticals Inc
1 Sep 21
Preliminary proxy
4:46pm
to the issuance thereof for any purpose. The Board of Directors does not intend to issue any common stock except on terms which the Board of Directors … determines it to be necessary or appropriate for the purpose of soliciting additional proxies to approve Proposal 1. We currently do not intend to propose
424B5
PCSA Processa Pharmaceuticals Inc
20 Aug 21
Prospectus supplement for primary offering
4:46pm
receive in connection with securities offered pursuant to this prospectus supplement for any purpose. Pending application of the net proceeds as described … broad discretion to allocate the net proceeds, if any, we receive in connection with securities offered pursuant to this prospectus for any purpose
8-K
EX-1.1
PCSA Processa Pharmaceuticals Inc
20 Aug 21
Entry into a Material Definitive Agreement
4:30pm
of the Registration Statement or any Rule 462(b) Registration Statement is in effect and no proceedings for such purpose have been instituted or are pending … or otherwise make available such proceeds to any subsidiary, joint venture partner or other person or entity, for the purpose of financing
10-Q
2021 Q2
PCSA Processa Pharmaceuticals Inc
12 Aug 21
Quarterly report
4:01pm
randomized, placebo-controlled study in patients with gastroparesis. The purpose of the Phase 2A trial is to evaluate the safety, efficacy
S-3
nbn1qh rx21
30 Jun 21
Shelf registration
4:02pm
S-3
EX-5.1
uyj1klg
30 Jun 21
Shelf registration
4:02pm
S-8
EX-5.1
zbca06ptrykd
30 Jun 21
Registration of securities for employees
4:02pm
S-8
n9usa8gw40kgddsi
30 Jun 21
Registration of securities for employees
4:02pm
8-K
EX-10.1
fmqa5n au3l9alrczzn
17 Jun 21
PROCESSA PHARMACEUTICALS ENTERS INTO A LICENSING AGREEMENT WITH OCUPHIRE PHARMA, INC., FOR the Development of RX-3117
11:35am
10-Q
ojk7 dwsb8378l
13 May 21
Quarterly report
4:30pm
DEF 14A
tndtd26
22 Apr 21
Definitive proxy
2:00pm
424B3
7g2949842r3 0v
12 Apr 21
Prospectus supplement
1:44pm
10-K/A
y4td88 xzz61hnu2
7 Apr 21
Annual report (amended)
4:23pm
S-3
nyoo va9635d6v4x67
1 Apr 21
Shelf registration
8:00pm
S-3
EX-5.1
e9i l290e
1 Apr 21
Shelf registration
8:00pm
10-K
ism2g4428hv901 fq20t
24 Mar 21
Annual report
8:00pm
8-K
EX-10.1
k6ihbmqd
18 Feb 21
Processa Pharmaceuticals Announces $10.2 Million Strategic Financing
10:08am
8-K
EX-10.2
ok6nrwzvc57e2c7w3
18 Feb 21
Processa Pharmaceuticals Announces $10.2 Million Strategic Financing
10:08am
8-K
EX-10.3
r9dfbrxxxwvr va6o6n8
18 Feb 21
Processa Pharmaceuticals Announces $10.2 Million Strategic Financing
10:08am